PC
CUE icon

PA Capital’s Cue Biopharma CUE Stock Holding History

PA Capital’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$705K Buy
1,562
+883
+130% +$509K 0.5% 73
2020
Q2 		$499K Sell
679
-678
-50% -$491K 0.36% 100
2020
Q1 		$578K Buy
+1,357
New +$658K 0.51% 73

Other funds holding CUE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return

PA Capital's CUE Position: Q3 2020 in Review

PA Capital increased its Cue Biopharma (CUE) stake by 130% in Q3 2020, buying an estimated $509K and bringing the position to 1,562 shares worth $705K. The position accounts for 0.5% of the portfolio, ranked #73.

PA Capital first reported a position in CUE in Q1 2020 and has held it in 3 quarters since. 92 funds tracked by Wall St. Rank hold CUE as of Q3 2020.

  • PA Capital held 1,562 shares of Cue Biopharma worth $705K as of Q3 2020.
  • PA Capital bought 883 Cue Biopharma shares in Q3 2020, an estimated $509K.
  • Cue Biopharma made up 0.5% of PA Capital's portfolio in Q3 2020, its #73 holding.
  • PA Capital first reported a position in Cue Biopharma in Q1 2020 and has held it in 3 quarters since.
  • 92 funds tracked by Wall St. Rank held Cue Biopharma as of Q3 2020.

Based on PA Capital's 13F filing for Q3 2020, filed 13 Nov 2020.